RUNX2 (RUNX Family Transcription Factor 2)

This study highlights CaMnP1000 as a biomaterial with enhanced osteogenic, angiogenic and possibly inflammatory properties. Future research should focus on the underlying mechanisms and manganese-doped CaPs for therapeutic purposes in bone healing.

Mechanistically, hypermethylation at cg08640619 disrupts RUNX2 binding, leading to inhibition of KIRREL1 and ETV3. Our study provides a comprehensive platform for understanding how genetic and epigenetic variants disrupt transcriptional programs in CRC, offering insights into disease susceptibility and identifying potential diagnostic and therapeutic targets.

Molecular docking identified a high-affinity interaction between sorafenib and KIF20A (binding energy: -6.11 kcal/mol), suggesting direct targeting. The current study unveiled KIF20A as a dual regulator of tumor-intrinsic malignancy and immune evasion, positioning sorafenib as a promising therapeutic agent to disrupt KIF20A-driven pathways in gastric adenocarcinoma.

Dental implant surgery in patients undergoing chemotherapy is frequently approached with caution, as these pharmacological treatments can impair bone metabolism and jeopardize the integration of the implant with the bone. This study investigated whether tamoxifen, a medication widely utilized in breast cancer therapy, could potentially enhance bone healing around titanium implants, specifically when administered alongside the chemotherapeutic agent cisplatin. Utilizing a laboratory model that simulates postmenopausal bone loss, the research demonstrated that tamoxifen significantly improved both the volume and the structural quality of the bone surrounding the implants, partially mitigating the adverse effects associated with cisplatin. These findings are of clinical importance as they suggest that a history of chemotherapy should not be considered a definitive barrier to successful dental rehabilitation. Instead, with appropriate pharmacological support, dental implant procedures may be a more viable and predictable treatment option for cancer survivors than previously recognized. This research provides a foundation for clinicians to better evaluate the feasibility of oral rehabilitation in this patient population, ultimately aiming to improve their long-term oral health and quality of life.

LncRNA H19 acts as a lineage-specific driver of osteogenic differentiation via the BMP2/NF-κB/Wnt5a axis. Targeting H19 represents a promising approach to promote bone regeneration and potentially modulate pathways associated with cancer-associated ostealgia.

Moreover, this review reveals the challenges in the contemporary research that are of critical importance: optimization of large-scale production and purification of ASC-Exos to provide uniformity in the clinical use; full clarification of the molecular processes that underlie ASC-Exos-mediated effects (e.g., metabolic reprogramming control in tumors); and the absence of detailed preclinical and clinical data on the long-term safety and efficacy. Finally, the review would serve as a valuable resource to developing fundamental research in the field of ASC-Exos and increasing the pace of its clinical application, especially when used together in conjunction with more sophisticated methods of drug delivery and tissue regeneration, to achieve new prospects in the treatment of incurable diseases and repair tissue in regenerative medicine.

This study provides evidence that immobilizing HDL onto biomaterial surfaces can simultaneously regulate immune responses and stimulate bone regeneration. Such multifunctional coatings offer a promising strategy to enhance osseointegration and long-term implant success, especially in high-risk patient groups such as individuals with diabetes or cancer.

This study highlights that the natural compound CEP exerts its antitumor effects by activating mitophagy-dependent ferroptosis through a multi-target effect. CEP thus shows great promise as a potential drug candidate for GC treatment.

RUNX1 knockdown suppressed HCC cell proliferation, migration, and invasion by attenuating Wnt/β-catenin/EMT signaling activity. These findings highlight RUNX1 as a potential prognostic biomarker and therapeutic target, offering mechanistic insight into HCC pathogenesis and avenues for improved precision oncology.

TAFA4 acts as a neuron-derived mediator of neuroimmune crosstalk in IVDD that modulates macrophage polarization and oxidative stress, thereby delaying disc degeneration. This neuron-immune axis represents a potential therapeutic target.

Pamidronate (APD), a nitrogen-containing bisphosphonate, has shown potential in managing osteolytic lesions by inhibiting osteoclast activity...Moreover, CHA exhibited excellent biocompatibility with no observed systemic toxicity. These results underscore the promise of CHA as a clinically translatable therapeutic strategy for the treatment of osteolytic bone metastases.

It can be concluded that, down-regulation of MAPK3 and KIT and up-regulation of BMP4 which are the consequence of microsecond PEF treatment inhibit medulloblastoma. The results exhibited the significant role of MAPK3 in response to microsecond PEF treatment.